http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-102129852-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-141 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-113 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-713 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-713 |
| filingDate | 2017-10-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2020-07-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2020-07-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-102129852-B1 |
| titleOfInvention | Small interfering RNA and Pharmaceutical Composition for Treatment of HPV related cancer comprising the same |
| abstract | The present invention relates to an RNA interference-inducing nucleic acid for suppressing cancer caused by human papilloma virus (hereinafter, HPV) infection, and more specifically, messenger RNA of E6 or E7 gene of HPV (messenger RNA; The sequence of the 5'-terminal region of a microRNA (microRNA; miRNA) capable of binding to mRNA) is complementary to the mRNA base of E6 or E7 of HPV and suppresses its expression, thereby effectively suppressing cancer. It relates to a RNA interference-inducible nucleic acid that can be treated. The RNA interference-inducing nucleic acid according to the present invention utilizes the problem of the microRNA-like off-target effect in reverse, and the 5'end of the RNA interference-inducing nucleic acid is mRNA of E6 or E7 of HPV By including the base sequence of the tumor suppressing microRNA capable of binding with, it suppresses the cancer by inhibiting the expression of the target HPV E6 and E7, and also functions as a cancer suppressing microRNA to further suppress cancer. Accordingly, it is possible to maximize cancer killing and suppression effects without off-target side effects. |
| priorityDate | 2016-10-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 245.